PTC Therapeutics Receives 2023 EURORDIS Black Pearl Company Award for Innovation
02/03/2023 - 08:00 AM
- This award recognizes PTC's 25-year legacy in discovering and delivering novel therapies that address the underlying cause of rare diseases -
SOUTH PLAINFIELD, N.J. , Feb. 3, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company has been named the winner of 2023 EURORDIS Black Pearl Company Award for Innovation. The Black Pearl Awards recognize and celebrate companies who have undertaken ground-breaking activities to advance rare disease research and medicine development.
"We are honored to accept this award and deeply appreciate the recognition of PTC's commitment to providing access to best-in-class treatments for people living with rare diseases with little to no treatment options," said Stuart W. Peltz , Ph.D., Chief Executive Officer, PTC Therapeutics. "This award is especially meaningful as we proudly celebrate our 25-year history of serving the rare disease community."
"We offer our hearty congratulations to PTC Therapeutics for winning the EURORDIS Black Pearl Company Award for Innovation," said Michael Wilbur , Chief Operating Officer, EURORDIS.
The EURORDIS Black Pearl Awards ceremony will be held on Feb. 21 in Brussels, Belgium . At the ceremony, EURORDIS also raises awareness for Rare Disease Day, an international campaign launched and coordinated by the organization to empower national rare disease alliances. It is observed on the last day of February each year.
About PTC Therapeutics, Inc.
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. PTC's mission is to provide access to best-in-class treatments for patients who have little to no treatment options. PTC's strategy is to leverage its strong scientific and clinical expertise and global commercial infrastructure to bring therapies to patients. PTC believes this allows it to maximize value for all its stakeholders. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, Instagram, LinkedIn, and Twitter at @PTCBio.
For More Information:
Investors: Kylie O'Keefe kokeefe@ptcbio.com
Media: Jeanine Clemente jclemente@ptcbio.com
https://www.prnewswire.com/news-releases/ptc-therapeutics-receives-2023-eurordis-black-pearl-company-award-for-innovation-301737933.html
SOURCE PTC Therapeutics, Inc.
PTCT Rankings
#4692 Ranked by Stock Gains
PTCT Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
South Plainfield
About PTCT
ptc is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. while ptc’s discovery programs are directed at targets in multiple therapeutic areas, ptc is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. ptc’s internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. for more information on the company, please visit our website www.ptcbio.com.
